Neurological Biomarkers Market Expected to Reach $18.9 Billion by 2031

Neurological biomarkers market size was valued at $5.4 billion in 2021, and is estimated to reach $18.9 billion by 2031, growing at a CAGR of 13.6% from 2022 to 2031. Ever-increasing rise in the incidence of Alzheimer's and Parkinson's is anticipated to contribute toward the robust growth of neurological biomarkers among these two applications. In addition, surge in adoption of neurological biomarkers in drug development and validation has increased over the years to improve the accuracy of clinical trials. Further, rise in transition toward personalized medicine is expected to offer profitable opportunities for the expansion of neurological biomarkers applied across Alzheimer's and Parkinson's.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
Biomérieux, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Merck KGAA, Myriad Genetics, Inc., Neurobio, Perkinelmer Inc., Quanterix, Shimadzu Corporation, Thermo Fisher Scientific

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/3555

However, the sales of neurological biomarkers product have witnessed hindrances, owing to the strict government regulations. The emerging ethical issues regarding early diagnosis of Alzheimer's disease, Parkinson's disease, and multiple Sclerosis is expected to impede the market growth. On the contrary, surge in healthcare investments in public as well as private sectors, increase in focus on developing cost-effective biomarker testing increase in patient population, and rise in demand for non-invasive diagnostic techniques for Alzheimer's and Parkinson's are anticipated to open new avenues for expansion of the neurological biomarkers market size during the forecast period.

Depending on product type, the genomic segment is expected to witness a significant CAGR during the forecast period in neurological biomarkers market analysis. The major factors that contribute toward the growth of the genomic biomarkers market include increase in prevalence of neurological diseases, rise in incidence rate of ischemic stroke, high demand for minimally invasive procedures, development of technologies in clinical laboratory tests, immense developments in infrastructure for data sharing and analysis such as bioinformatics, and growing awareness about genomics biomarker-based personalized medicines. The rise in development of personalized medicines based on a specific genetic sequence of individual is projected to help propel the growth of the genomic biomarker segment in neurological biomarkers Market.

𝐁𝐮𝐲 𝐍𝐨𝐰 https://www.alliedmarketresearch.com/checkout-final/daf521227a87e3b3545e311b016d36f1

On the basis of application of neurological biomarkers, the multiple sclerosis segment is expected to witness a significant CAGR during the forecast period. Rise in incidence rate of multiple sclerosis boot the growth of neurological biomarker market. For instance, according to National Multiple Sclerosis Society 2019, between 750,000 and 1 million people in the U.S. over the age of 18 are living with MS. There are more people living with MS in the Northeast and Midwest than in the South. The rates of MS have increased worldwide since 1955. The first report of MS in the U.S. was published in 1976 and found 123,00 cases. A study from 1990 found 300,000 cases of MS. This compares to the estimated 750,000 to 1 million cases in 2019.

On the basis of region, Asia-Pacific is expected to witness highest CAGR during the forecast period in neurological biomarkers market forecast, owing to rise in geriatric population and the launch of various products in the region to fulfill the growing demands. Additionally, the development of human-induced pluripotent stem cells (iPS) for early diagnosis of Parkinson's disease in Japan is a recent trend, which is being followed. In addition, the rise in population in Japan is on an increase and the number has reached to 126.26 million individuals as of 2019. Therefore, such increase in population which is more susceptible to Parkinson's disease is anticipated to help supplement the neurological biomarkers industry growth.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/3555

𝐊𝐄𝐘 𝐅𝐈𝐍𝐃𝐈𝐍𝐆𝐒 𝐎𝐅 𝐓𝐇𝐄 𝐒𝐓𝐔𝐃𝐘

By product type, the proteomic segment held the largest share in the neurological biomarkers market share in 2021.

By application, the Alzheimer's disease segment held the largest share in the neurological biomarkers market trends in 2021, and is expected to remain dominant during the forecast period.

By region, North America held the largest market share in neurological biomarkers industry in 2021.

Contact:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.